FDA APPROVES ORAL FORMULATION OF ABILIFY

Bristol-Myers Squibb and Otsuka Pharmaceutical have received approval from the FDA for an oral solution formulation of Abilify, a treatment for schizophrenia and acute manic and mixed episodes associated with bipolar disorder.

The companies said the oral formulation of Abilify (aripiprazole) will be available in pharmacies beginning in February.